Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert D Hubbard

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Chemmedchem|November 8, 2006
Advances towards the development of ATP-competitive small-molecule inhibitors of the insulin-like growth factor receptor (IGF-IR)Robert D Hubbard, Julie L Wilsbacher
Journal of the American Chemical Society|March 21, 2002
Three-component cycloadditions: the first transition metal-catalyzed [5+2+1] cycloaddition reactionsPaul A Wender, Gabriel G Gamber, Robert D Hubbard, et al.
Journal of the American Chemical Society|May 2, 2002
Total synthesis of (-)-laulimalidePaul A Wender, Sayee G Hegde, Robert D Hubbard, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentEvan P Lebois, Chinnappa D Kodira, Robert D Hubbard, et al.
Journal of the American Chemical Society|March 3, 2005
Multicomponent cycloadditions: the four-component [5+1+2+1] cycloaddition of vinylcyclopropanes, alkynes, and COPaul A Wender, Gabriel G Gamber, Robert D Hubbard, et al.
Organic Letters|September 12, 2003
Synthesis and biological evaluation of (-)-laulimalide analoguesPaul A Wender, Sayee G Hegde, Robert D Hubbard, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 13, 2023
Rational design of proteasome inhibitors based on the structure of the endogenous inhibitor PI31/Fub1Benjamin Velez, Aida Razi, Robert D Hubbard, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 27, 2004
Microtubule-stabilizing agents based on designed laulimalide analoguesSusan L Mooberry, Deborah A Randall-Hlubek, Rachel M Leal, et al.
Journal of Drug Targeting|January 5, 2012
Cationic lipids percentage and processing temperature are critical in designing siRNA lipid nanoparticlesXiaobin Zhao, Yemin Liu, Jingfeng Song, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2008
Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidinesRobert D Hubbard, Scott H Dickerson, Holly K Emerson, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Chemmedchem|November 8, 2006
Advances towards the development of ATP-competitive small-molecule inhibitors of the insulin-like growth factor receptor (IGF-IR)Robert D Hubbard, Julie L Wilsbacher
Journal of the American Chemical Society|March 21, 2002
Three-component cycloadditions: the first transition metal-catalyzed [5+2+1] cycloaddition reactionsPaul A Wender, Gabriel G Gamber, Robert D Hubbard, et al.
Journal of the American Chemical Society|May 2, 2002
Total synthesis of (-)-laulimalidePaul A Wender, Sayee G Hegde, Robert D Hubbard, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentEvan P Lebois, Chinnappa D Kodira, Robert D Hubbard, et al.
Journal of the American Chemical Society|March 3, 2005
Multicomponent cycloadditions: the four-component [5+1+2+1] cycloaddition of vinylcyclopropanes, alkynes, and COPaul A Wender, Gabriel G Gamber, Robert D Hubbard, et al.
Organic Letters|September 12, 2003
Synthesis and biological evaluation of (-)-laulimalide analoguesPaul A Wender, Sayee G Hegde, Robert D Hubbard, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 13, 2023
Rational design of proteasome inhibitors based on the structure of the endogenous inhibitor PI31/Fub1Benjamin Velez, Aida Razi, Robert D Hubbard, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 27, 2004
Microtubule-stabilizing agents based on designed laulimalide analoguesSusan L Mooberry, Deborah A Randall-Hlubek, Rachel M Leal, et al.
Journal of Drug Targeting|January 5, 2012
Cationic lipids percentage and processing temperature are critical in designing siRNA lipid nanoparticlesXiaobin Zhao, Yemin Liu, Jingfeng Song, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2008
Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidinesRobert D Hubbard, Scott H Dickerson, Holly K Emerson, et al.
Pageof 3